Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corvus Pharmaceuticals (CRVS) Cash from Operations (2022 - 2025)

Historic Cash from Operations for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to -$9.6 million.

  • Corvus Pharmaceuticals' Cash from Operations fell 5133.68% to -$9.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$32.1 million, marking a year-over-year decrease of 4494.71%. This contributed to the annual value of -$25.4 million for FY2024, which is 622.1% down from last year.
  • As of Q3 2025, Corvus Pharmaceuticals' Cash from Operations stood at -$9.6 million, which was down 5133.68% from -$5.8 million recorded in Q2 2025.
  • Over the past 5 years, Corvus Pharmaceuticals' Cash from Operations peaked at -$5.2 million during Q1 2024, and registered a low of -$9.6 million during Q3 2025.
  • Its 4-year average for Cash from Operations is -$6.7 million, with a median of -$6.3 million in 2024.
  • Over the last 5 years, Corvus Pharmaceuticals' Cash from Operations had its largest YoY gain of 3641.97% in 2024, and its largest YoY loss of 6382.81% in 2024.
  • Over the past 4 years, Corvus Pharmaceuticals' Cash from Operations (Quarter) stood at -$7.5 million in 2022, then surged by 31.54% to -$5.2 million in 2023, then plummeted by 63.83% to -$8.5 million in 2024, then fell by 13.01% to -$9.6 million in 2025.
  • Its Cash from Operations was -$9.6 million in Q3 2025, compared to -$5.8 million in Q2 2025 and -$8.3 million in Q1 2025.